Publicaciones en las que colabora con Elisa Lozano Esteban (13)

2024

  1. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

2020

  1. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression

    Hepatology, Vol. 72, Núm. 3, pp. 949-964

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2018

  1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

  2. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

    Oncotarget, Vol. 9, Núm. 47, pp. 28474-28485

  3. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477

2017

  1. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

2016

  1. Mechanisms of resistance to chemotherapy in gastric cancer

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 16, Núm. 3, pp. 318-334

2015

  1. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)

    Journal of Controlled Release, Vol. 216, pp. 93-102

2014

  1. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development

    Molecular Cancer Research, Vol. 12, Núm. 1, pp. 91-100

  2. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

2013

  1. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

    Hepatology, Vol. 58, Núm. 3, pp. 1065-1073